SCHEMBL7656766

SCHEMBL7656766

Cc1nc2ccc(C(=O)NS(=O)(=O)c3ccc(Cl)s3)cc2n1Cc1ccc(Cl)cc1Cl

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.67
PTGER3 P43115 5/20 0.45
HDAC1 Q13547 4/20 0.43
HDAC6 Q9UBN7 4/20 0.43
HDAC8 Q9BY41 3/20 0.43
HDAC3 O15379 2/20 0.43
HDAC4 P56524 2/20 0.43
HDAC7 Q8WUI4 2/20 0.43
HDAC2 Q92769 2/20 0.43
HDAC10 Q969S8 2/20 0.43
HDAC11 Q96DB2 2/20 0.43
HDAC9 Q9UKV0 2/20 0.43
HDAC5 Q9UQL6 2/20 0.43
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
LMNA P02545 1/20 0.41
EPHX2 P34913 1/20 0.41
ALDH1A1 P00352 2/20 0.39
P2RY12 Q9H244 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7652854 0.92 PPARG (0.56) PPARGPTGER3HDAC1HDAC6HDAC8
SCHEMBL7656318 0.92 PPARG (0.65) PPARGPTGER3HDAC1HDAC6HDAC8
SCHEMBL6308625 0.89 PPARG (0.54) PPARGPTGER3HDAC1HDAC6HDAC8
SCHEMBL7652833 0.89 PPARG (0.54) PPARGHDAC1HDAC6HDAC8HDAC3
SCHEMBL6308886 0.87 PPARG (0.61) PPARGHDAC1HDAC6HDAC8HDAC3
SCHEMBL6307995 0.86 PPARG (0.51) PPARGPTGER3HDAC1HDAC6HDAC8
SCHEMBL6303321 0.85 PPARG (0.50) PPARGHDAC1HDAC6HDAC8HDAC3
SCHEMBL1160394 0.85 PPARG (0.70) PPARGHDAC1HDAC6HDAC8HDAC3
SCHEMBL6134973 0.85 PPARG (0.70) PPARGHDAC1HDAC6HDAC8HDAC3
SCHEMBL8118233 0.85 PPARG (0.56) PPARGHDAC1HDAC6HDAC8HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP claimed
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP disclosed